In 2018, a PARP inhibitor, Olaparib, received full FDA approval for the treatment of BRCA1/2-mutated breast and ovarian cancer, becoming the first therapy to utilize the principle of synthetic lethality, marking a considerable step forward in the pursuit of effective cancer therapeutics [22]. The gene discussed is BRCA1; the disease is cancer.